FORA Stock Overview
Forian Inc. provides software solutions, proprietary data driven insights, and predictive analytics to optimize the operational, clinical, and financial performance of its healthcare, cannabis, and government customers.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.01|
|52 Week High||US$12.56|
|52 Week Low||US$2.56|
|1 Month Change||-26.29%|
|3 Month Change||34.56%|
|1 Year Change||-64.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-82.49%|
Recent News & Updates
|FORA||US Healthcare Services||US Market|
Return vs Industry: FORA underperformed the US Healthcare Services industry which returned -43.4% over the past year.
Return vs Market: FORA underperformed the US Market which returned -13% over the past year.
|FORA Average Weekly Movement||15.6%|
|Healthcare Services Industry Average Movement||12.0%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.2%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: FORA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: FORA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Forian Inc. provides software solutions, proprietary data driven insights, and predictive analytics to optimize the operational, clinical, and financial performance of its healthcare, cannabis, and government customers. It operates through three segments: Information & Software, Services, and Other. The company’s products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides clients with a presentation of business performance.
Forian Fundamentals Summary
|FORA fundamental statistics|
Is FORA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FORA income statement (TTM)|
|Cost of Revenue||US$5.83m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
|Earnings per share (EPS)||-1.06|
|Net Profit Margin||-156.53%|
How did FORA perform over the long term?See historical performance and comparison
Is FORA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FORA?
Other financial metrics that can be useful for relative valuation.
|What is FORA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does FORA's PS Ratio compare to its peers?
|FORA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TRHC Tabula Rasa HealthCare
STRM Streamline Health Solutions
Price-To-Sales vs Peers: FORA is expensive based on its Price-To-Sales Ratio (5.9x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does FORA's PE Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: FORA is expensive based on its Price-To-Sales Ratio (5.9x) compared to the US Healthcare Services industry average (2.8x)
Price to Sales Ratio vs Fair Ratio
What is FORA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.9x|
|Fair PS Ratio||7.9x|
Price-To-Sales vs Fair Ratio: FORA is good value based on its Price-To-Sales Ratio (5.9x) compared to the estimated Fair Price-To-Sales Ratio (7.9x).
Share Price vs Fair Value
What is the Fair Price of FORA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate FORA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate FORA's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Forian forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FORA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FORA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FORA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FORA's revenue (31.2% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: FORA's revenue (31.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FORA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Forian performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: FORA is currently unprofitable.
Growing Profit Margin: FORA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if FORA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare FORA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FORA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (2.7%).
Return on Equity
High ROE: FORA has a negative Return on Equity (-159.69%), as it is currently unprofitable.
Discover strong past performing companies
How is Forian's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: FORA's short term assets ($33.3M) exceed its short term liabilities ($8.2M).
Long Term Liabilities: FORA's short term assets ($33.3M) exceed its long term liabilities ($25.0M).
Debt to Equity History and Analysis
Debt Level: FORA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if FORA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FORA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FORA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 90.3% each year
Discover healthy companies
What is Forian current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FORA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FORA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FORA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FORA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FORA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Barton (57 yo)
Mr. Daniel J. Barton, also known as Dan, serves as Chief Executive Officer and Director of Forian Inc. since March 2021. Mr. Barton also served as Chief Executive Officer of Medical Outcomes Research Analy...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD207.39K) is below average for companies of similar size in the US market ($USD763.69K).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Experienced Management: FORA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: FORA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
Forian Inc.'s employee growth, exchange listings and data sources
- Name: Forian Inc.
- Ticker: FORA
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$128.067m
- Shares outstanding: 31.94m
- Website: https://forian.com
Number of Employees
- Forian Inc.
- 41 University Drive
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.